Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
For example, the latter could be reduced with hydrogen to 249CfBr2, but the former could not – this result was reproduced on individual 249BkBr3 and 249CfBr3 samples, as well on the samples containing both bromides. The intergrowth of californium in berkelium occurs at a rate of 0.22% per day and is an obstacle to studying berkelium properties. Beside a chemical contamination, 249Cf, being an alpha emitter, brings undesirable self-damage of the crystal lattice and the resulting self-heating. The chemical effect however can be avoided by performing measurements as a function of time and extrapolating the obtained results.
==== Agent Abrella ==== Rainian Agent Abrella (レイン星人エージェント・アブレラ, Rein Seijin Ējento Aburera) is a bat-themed arms dealer from Planet Rain and an infamous figure in the intergalactic black market who is known for causing wars in seven galaxies, destroying billions of lives in the process. As his homeworld's name suggests, it is perpetually raining, forcing him to wear a special helmet that produces an artificial rainy environment to sustain himself on other worlds. After arriving on Earth, he offers his services, as well as Mechanoids and Kaijuki, to his fellow Alienizers for the right price. Initially staying in the shadows, Abrella gathers information on the Deka Base from clients who have successfully infiltrated it and escaped with their lives while planning to eventually realize his desire for a "world of...currency and crime". After eventually making his presence known to the Dekarangers and losing a Browgoul he intended to raise to them, Abrella starts taking their interference personally and launches a failed smear campaign against them. Following this, Abrella takes advantage of the Dekarangers' fight with the Alienizer Jellyfis to break four Alienizers out of prison and lead them in taking over the Deka Base. From there, he uses Deka Base Robo to go on a rampage, lure the bulk of S.P.D.'s forces to Earth, and uses their planetary forcefield against them. While the Dekarangers eventually retake Deka Base Robo and use the D-Bazooka to delete Abrella, he was succeeded by his pupil, Agent X, as of the crossover film Mahō Sentai Magiranger vs. Dekaranger.
The character was introduced during the serial's 2019 season finale, which saw several characters held hostage at gunpoint in the local hospital. Kipa-Williams explained that Ari's boss sends him to the hospital after he sustains a cut to his arm while working on a construction site. Shortly after Ari arrives, armed men from the Ouroboros gang take everyone on that floor hostage. When the hostages are rounded up, Ari is forced to sit next to "a terrified" Marilyn Chambers (Emily Symons), who he instantly tries to help and reassure. Kipa-Williams told Rachel Lucas of What's on TV: "Ari comes from a past where he's not unfamiliar with bad guys. He's relatively calm, he's very aware and he's strategizing a way to get the hostages – or himself – out." Knowing that they need to gain "control of the situation", Ari teams up with Mason Morgan (Orpheus Pledger) and they devise an escape plan. Ari leads most of the hostages out of the building, while Mason tries to distract the gunmen, which results in his death when he is shot. Kipa-Williams likened the filming of the storyline to a feature film, saying "We spent quite a number of days in the hospital set and at the exterior of the hospital so my first few days filming were quite intense. It was a really nice welcome!" The actor was also grateful that he shared his first scenes with Symons. After the scenes aired, it was confirmed that Ari's family would soon be introduced and that they would be hiding some secrets. The Paratas later move in with Marilyn and her husband John Palmer (Shane Withington).
Duodenum: A short structure (about 20–25 cm long) that receives chyme from the stomach, together with pancreatic juice containing digestive enzymes and bile from the gall bladder. The digestive enzymes break down proteins, and bile emulsifies fats into micelles. The duodenum contains Brunner's glands which produce a mucus-rich alkaline secretion containing bicarbonate. These secretions, in combination with bicarbonate from the pancreas, neutralize the stomach acids contained in the chyme. Jejunum: This is the midsection of the small intestine, connecting the duodenum to the ileum. It is about 2.5 m (8.2 ft) long and contains the circular folds also known as plicae circulares and villi that increase its surface area. Products of digestion (sugars, amino acids, and fatty acids) are absorbed into the bloodstream here. Ileum: The final section of the small intestine. It is about 3 m long, and contains villi similar to the jejunum. It absorbs mainly vitamin B12 and bile acids, as well as any other remaining nutrients.
Metabolic myopathies are myopathies that result from defects in biochemical metabolism that primarily affect muscle. They are generally genetic defects (inborn errors of metabolism) that interfere with the ability to create energy, causing a low ATP reservoir within the muscle cell.
Sources: en.wikipedia.org
== Causes == The cause of the scarring in UIP may be known (less commonly) or unknown (more commonly). Since the medical term for conditions of unknown cause is "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). Examples of known causes of UIP include connective tissue diseases (primarily rheumatoid arthritis), drug toxicity, chronic hypersensitivity pneumonitis, asbestosis and Hermansky–Pudlak syndrome.
The earliest description and illustration of gigantomastia dates to 1669. In July of that year the Plymouth physician William Durston wrote to the Royal Society, reporting the case of a patient named Elizabeth Travers. Durston's account was soon published in the Society's Philosophical Transactions, and includes the following account of the onset of symptoms:Elizabeth Treves, [sic] 23. or 24. years of age, fair of complexion, brown-hair'd, of an healthy constitution, low of stature, of honest repute, but of mean and poor parentage, near this Town [Plymouth], was on Friday July 3d, 1669 in good health, and went well to bed, where she took as good rest and sleep, as ever before, but in the morning, when she awaken'd, and attempted to turn herself in her bed, was not able, finding her Breasts so swell'd, that she was affrighted to an astonishment. Then endeavoring to sit up, the weight of her Breasts fastned her to her bed; where she hath layn ever since, yet without all pain and weakness either in her Breasts, or in any other part.Durston later wrote to the Society to report that Travers had died on October 21 of the same year, four months after the onset of enlargement. One breast removed after the woman's death weighed 64 lb (29 kg).
Grassroots lobbying also influenced the Tobacco Products Directive decision. Tobacco companies have worked with organizations conceived to promote e-cigarette use, and these organizations have worked to hamper legislation intended at restricting e-cigarette use.
== From intermediates of the citric acid cycle and other pathways == Nonessential amino acids are produced in the body. The pathways for the synthesis of nonessential amino acids come from basic metabolic pathways. Glutamate dehydrogenase catalyzes the reductive amination of α-ketoglutarate to glutamate. A transamination reaction takes place in the synthesis of most amino acids. At this step, the chirality of the amino acid is established. Alanine and aspartate are synthesized by the transamination of pyruvate and oxaloacetate, respectively. Glutamine is synthesized from NH4+ and glutamate, and asparagine is synthesized similarly. Proline and arginine are both derived from glutamate. Serine, formed from 3-phosphoglycerate, which comes from glycolysis, is the precursor of glycine and cysteine. Tyrosine is synthesized by the hydroxylation of phenylalanine, which is an essential amino acid.
Sources: en.wikipedia.org
=== Indigenous peoples === The first inhabitants of North America are generally hypothesized to have migrated from Siberia by way of the Bering land bridge and arrived at least 14,000 years ago. The Paleo-Indian archaeological sites at Old Crow Flats and Bluefish Caves are two of the oldest sites of human habitation in Canada. The characteristics of Indigenous societies included permanent settlements, agriculture, complex societal hierarchies, and trading networks. Some of these cultures had collapsed by the time European explorers arrived in the late 15th and early 16th centuries and have only been discovered through archaeological investigations. Indigenous peoples in present-day Canada include the First Nations, Inuit, and Métis, the last being of mixed descent who originated in the mid-17th century when First Nations people married European settlers and their offspring subsequently developed their own identity. The Indigenous population at the time of the first European settlements is estimated to have been between 200,000 and two million, with a figure of 500,000 accepted by Canada's Royal Commission on Aboriginal Peoples. As a consequence of European colonization, the Indigenous population declined by forty to eighty percent. The decline is attributed to several causes, including the transfer of European diseases, to which they had no natural immunity, conflicts over the fur trade, conflicts with the colonial authorities and settlers, and the loss of Indigenous lands to settlers and the subsequent collapse of several nations' self-sufficiency.
given a Literature prize from the city of Zurich, 1932 made Titular Professor of the Swiss Federal Institute of Technology in Zurich, ETH 1935 appointed Honorary Member of the Royal Society of Medicine 1939 given a Festschrift at Eranos 1945 appointed President of the Society of Analytical Psychology, London, 1946 given a Festschrift by students and friends in 1955 named Honorary citizen of Küsnacht 1960, on his 85th birthday
The two substrates of this enzyme are the bile acid, cholic acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 7-ketodeoxycholic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 7alpha-hydroxysteroid:NAD+ 7-oxidoreductase. Other names in common use include 7alpha-hydroxy steroid dehydrogenase, and 7alpha-HSDH.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.